Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TECHNOLOGY LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
5 REGULATIONS: EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET
5.1 ROLE OF FDA
5.2 ROLE OF CDC AND HCFA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 HIGH PREVALENCE OF CANCER
6.1.2 ADVANTAGES OF LIQUID BIOPSY OVER SURGICAL BIOPSY
6.1.3 GOVERNMENT INITIATIVES TO SPREAD AWARENESS ABOUT EARLY DIAGNOSIS OF CANCER
6.1.4 RISE IN FDA APPROVAL
6.1.5 HEALTHCARE REIMBURSEMENT FOR LIQUID BIOPSY
6.2 RESTRAINTS
6.2.1 DOWNSIDES OF LIQUID BIOPSY
6.2.2 RAPID DEVELOPMENT OF ULTRASENSITIVE IMAGING TECHNOLOGIES SUCH AS MAGNETIC RESONANCE IMAGING
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
6.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
6.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES
6.3.4 HUGE MARKET POTENTIAL IN DEVELOPING COUNTRIES
6.4 CHALLENGES
6.4.1 SHORTAGE OF SKILLED PERSONNEL
6.4.2 LACK OF ACCESSIBILITY
7 COVID-19 IMPACT ON EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY
7.4 KEY INITIATIVES BY MARKET PLAYER DURING COVID 19
7.5 CONCLUSION:
8 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 CTC DETECTION METHODS
8.3 CTC ENRICHMENT METHODS
8.4 EX VIVO POSITIVE SELECTION
8.5 MOLECULAR (RNA)-BASED TECHNOLOGIES
8.6 FUNCTIONAL IN VITRO CELL INVASION ASSAY
8.7 XENOTRANSPLANTATION MODELS
8.8 MICROCHIPS
8.9 SINGLE SPIRAL MICROCHANNEL
8.1 NEGATIVE SELECTION
8.11 IMMUNOCYTOCHEMICAL TECHNOLOGIES
9 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 CANCER STEM CELL RESEARCH
9.3 MULTIPLE CHROMOSOME ABNORMALITIES
9.4 OTHERS
10 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER
10.1 OVERVIEW
10.2 RESEARCH & ACADEMIC INSTITUTES
10.3 REFERENCE LABORATORIES
10.4 HOSPITALS AND PHYSICIAN LABORATORIES
11 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION
11.1 EUROPE
11.1.1 GERMANY
11.1.2 FRANCE
11.1.3 U.K.
11.1.4 ITALY
11.1.5 RUSSIA
11.1.6 SPAIN
11.1.7 TURKEY
11.1.8 NETHERLANDS
11.1.9 SWITZERLAND
11.1.10 BELGIUM
11.1.11 REST OF EUROPE
12 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 GUARDANT HEALTH
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 EUROFINS GENOMICS (A SUBSIDIARY OF EUROFINS SCIENTIFIC)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 FOUNDATION MEDICINE, INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 COMPANY SHARE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENTS
14.4 ILLUMINA, INC.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 NATERA, INC.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 BIO-RAD LABORATORIES, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 QIAGEN
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 THERMO FISHER SCIENTIFIC INC.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENTS
14.9 BIOCEPT, INC.
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.9.4 RECENT DEVELOPMENT
14.1 BIOLIDICS LIMITED
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENTS
14.11 EXACT SCIENCES CORPORATION
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 EXODX (A SUBSIDIARY OF BIO-TECHNE CORPORATION)
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENTS
14.13 F. HOFFMANN-LA ROCHE LTD
14.13.1 COMPANY SNAPSHOT
14.13.2 RECENT FINANCIALS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENTS
14.14 IMMUCOR
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENTS
14.15 INIVATA LTD
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENTS
14.16 LUCENCE HEALTH, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
14.17 LUNGLIFE AI, INC.
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENTS
14.18 MDXHEALTH
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENT
14.19 MENARINI SILICON BIOSYSTEMS
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENTS
14.2 MYRIAD GENETICS, INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
14.21 VORTEX BIOSCIENCES
14.21.1 COMPANY SNAPSHOT
14.21.2 PRODUCT PORTFOLIO
14.21.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
List of Table
TABLE 1 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 2 EUROPE CTC DETECTION METHODS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 EUROPE CTC ENRICHMENT METHODS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE EX VIVO POSITIVE SELECTION IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE MOLECULAR (RNA)-BASED TECHNOLOGIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE FUNCTIONAL IN VITRO CELL INVASION ASSAY IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 EUROPE XENOTRANSPLANTATION MODELS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE MICROCHIPS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 EUROPE SINGLE SPIRAL MICROCHANNEL IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE NEGATIVE SELECTION IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE IMMUNOCYTOCHEMICAL TECHNOLOGIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE CANCER STEM CELL RESEARCH IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE MULTIPLE CHROMOSOME ABNORMALITIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE OTHERS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 17 EUROPE RESEARCH & ACADEMIC INSTITUTES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE REFERENCE LABORATORIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE HOSPITALS AND PHYSICIAN LABORATORIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 21 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 22 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 24 GERMANY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 25 GERMANY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 26 GERMANY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 27 FRANCE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 28 FRANCE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 29 FRANCE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 30 U.K. CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 31 U.K. CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 32 U.K. CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 33 ITALY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 34 ITALY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 35 ITALY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 36 RUSSIA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 37 RUSSIA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 38 RUSSIA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 39 SPAIN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 40 SPAIN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 41 SPAIN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 42 TURKEY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 43 TURKEY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 44 TURKEY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 45 NETHERLANDS CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 46 NETHERLANDS CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 47 NETHERLANDS CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 48 SWITZERLAND CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 49 SWITZERLAND CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 50 SWITZERLAND CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 51 BELGIUM CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
TABLE 52 BELGIUM CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 53 BELGIUM CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 REST OF EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 2 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: DROC ANALYSIS
FIGURE 4 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET : EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: SEGMENTATION
FIGURE 11 THE HIGH PREVALENCE OF CANCER IS EXPECTED TO DRIVE THE EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 CTC DETECTION METHODS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET
FIGURE 15 PREVALENCE OF BREAST CANCER IN EUROPE, INDIA, AND IN THE U.S.
FIGURE 16 PREVALENCE OF LUNG CANCER IN VARIOUS COUNTRIES, WITH HUNGARY BEING THE HIGHEST PREVALENCE RATE IN WOMEN AND MEN
FIGURE 17 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2021
FIGURE 18 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2020-2029 (USD MILLION)
FIGURE 19 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, CAGR (2022-2029)
FIGURE 20 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 21 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, 2021
FIGURE 22 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, 2020-2029 (USD MILLION)
FIGURE 23 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 24 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 25 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, 2021
FIGURE 26 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 27 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, CAGR (2022-2029)
FIGURE 28 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: SNAPSHOT (2021)
FIGURE 30 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY COUNTRY (2021)
FIGURE 31 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY COUNTRY (2022 & 2029)
FIGURE 32 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY COUNTRY (2021 & 2029)
FIGURE 33 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY (2022-2029)
FIGURE 34 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: COMPANY SHARE 2021 (%)
